These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 8708728

  • 21. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
    Tulpule A, Yung RC, Wernz J, Espina BM, Myers A, Scadden DT, Cabriales S, Ilaw M, Boswell W, Gill PS.
    J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
    [Abstract] [Full Text] [Related]

  • 22. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine.
    Osoba D, Northfelt DW, Budd DW, Himmelberger D.
    Cancer Invest; 2001 Oct; 19(6):573-80. PubMed ID: 11486699
    [Abstract] [Full Text] [Related]

  • 23. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.
    Harrison M, Tomlinson D, Stewart S.
    J Clin Oncol; 1995 Apr; 13(4):914-20. PubMed ID: 7707119
    [Abstract] [Full Text] [Related]

  • 24. Liposomal chemotherapies.
    Smart T.
    GMHC Treat Issues; 1995 Apr; 9(7/8):13. PubMed ID: 11362653
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
    Bennett CL, Golub RM, Stinson TJ, Aboulafia DM, von Roenn J, Bogner J, Goebel FD, Stewart S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug 15; 18(5):460-5. PubMed ID: 9715842
    [Abstract] [Full Text] [Related]

  • 26. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.
    Nasti G, Errante D, Santarossa S, Vaccher E, Tirelli U.
    Drug Saf; 1999 May 15; 20(5):403-25. PubMed ID: 10348092
    [Abstract] [Full Text] [Related]

  • 27. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
    Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS.
    Cancer; 2002 Jul 01; 95(1):147-54. PubMed ID: 12115328
    [Abstract] [Full Text] [Related]

  • 28. Liposomal KS drugs approved.
    GMHC Treat Issues; 1996 Apr 01; 10(4):8-9. PubMed ID: 11363710
    [Abstract] [Full Text] [Related]

  • 29. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L, Zucchetti M, Parisi I, Viganò MG, Zecca B, Careddu A, D'Incalci M, Lazzarin A.
    Cancer Chemother Pharmacol; 2000 Apr 01; 45(6):495-501. PubMed ID: 10854138
    [Abstract] [Full Text] [Related]

  • 30. Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome.
    Gelmann EP, Longo D, Lane HC, Fauci AS, Masur H, Wesley M, Preble OT, Jacob J, Steis R.
    Am J Med; 1987 Mar 01; 82(3):456-62. PubMed ID: 2435150
    [Abstract] [Full Text] [Related]

  • 31. NeXstar Pharmaceuticals lauches DaunoXome.
    J Int Assoc Physicians AIDS Care; 1996 Jun 01; 2(6):52. PubMed ID: 11363700
    [Abstract] [Full Text] [Related]

  • 32. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ, Spencer CM.
    Drugs; 1997 Mar 01; 53(3):520-38. PubMed ID: 9074848
    [Abstract] [Full Text] [Related]

  • 33. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
    Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC.
    Clin Oncol (R Coll Radiol); 1993 Mar 01; 5(6):367-71. PubMed ID: 8305357
    [Abstract] [Full Text] [Related]

  • 34. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
    J Int Assoc Physicians AIDS Care; 1996 May 01; 2(5):50-1. PubMed ID: 11363534
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Advanced epidemic Kaposi's sarcoma: treatment with bleomycin or combination of doxorubicin, bleomycin, and vincristine.
    Hernández DE, Pérez JR.
    Int J Dermatol; 1996 Nov 01; 35(11):831-3. PubMed ID: 8915746
    [Abstract] [Full Text] [Related]

  • 37. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
    Cabriales S, Bresnahan J, Testa D, Espina BM, Scadden DT, Ross M, Gill PS.
    Oncol Nurs Forum; 1998 Nov 01; 25(1):67-70. PubMed ID: 9460774
    [Abstract] [Full Text] [Related]

  • 38. DOXIL superior for KS.
    Posit Aware; 1995 Nov 01; ():7. PubMed ID: 11362576
    [Abstract] [Full Text] [Related]

  • 39. Liposomal daunorubicin as treatment for Kaposi's sarcoma.
    Petre CE, Dittmer DP.
    Int J Nanomedicine; 2007 Nov 01; 2(3):277-88. PubMed ID: 18019828
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.